Lencioni, Riccardo

Hepatocellular carcinoma

Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 7,055

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., & Lencioni, R. (2021) · Nature Reviews Gastroenterology & Hepatology

Hepatocellular Carcinoma Treatment and PrognosisRenal cell carcinoma treatment

Cited by 1,044

The Etiology of Hepatocellular Carcinoma and Consequences for Treatment

Sanyal, A. J., Yoon, S. K., & Lencioni, R. (2010) · The Oncologist

Hepatocellular Carcinoma Treatment and PrognosisHepatitis B Virus Studies

Cited by 517

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology

Hepatocellular Carcinoma Treatment and PrognosisStatistical Methods in Clinical Trials

Cited by 413

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

Sangro, B., Kudo, M., Erinjeri, J. P., Qin, S., Ren, Z., Chan, S. L., Arai, Y., Heo, J., Mai, A., Escobar, J., et al. (2025) · The Lancet

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 333